Brief Review of High-Dose Chemotherapy and Autologous Stem Cell Transplant in the Elderly with Primary CNS Lymphoma— Schorb 2020

This is a brief audio review. In the article High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. published, 2020 by Schorb and Colleagues, The outcomes and key points are as noted: In specific adults responding to induction, high dose chemotherapy with autologous hematopoietic stem cell therapy rescue may be effective. At median 41 months follow up, 13 patients achieved remission, 1 mortality noted related to disease progression. The 2 year progression free survival was 92.9%, overall survival was 92.3%. 8 serious adverse events were noted to be related to the treatment. This was a Prospective, open label; (Single-arm pilot) with 14 patients who were patients older than 65 years old, immunocompetent, biopsy confirmed primary diffuse large B-cell lymphoma of the central nervous system (central nervous system lymphoma).

Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020 Jul 28;4(14):3378-3381. doi: 10.1182/bloodadvances.2020002064. PMID: 32722778; PMCID: PMC7391148.